Neofect Co.Ltd (290660) Fair Value & Analysis
Healthcare · KR · Market cap 69.8B KRW (≈ $48.8M) · ISIN KR7290660000
What is Neofect Co.Ltd really worth?
Below-average quality, and trading another 480% above our fair value of 305.46 KRW.
Risks
Fair value as of: Aug 24, 2026
From 1 valuation models · updated 9 days ago
Share price +3.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (381.82 KRW). The favourable scenario is already priced in.
- Weak quality (15/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (201.60 KRW to 381.82 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 24, 2026.
How to read this chart
60‑month range 1,273 KRW – 9,080 KRW · fair‑value band 201.60 KRW – 381.82 KRW · the 1,771 KRW price screens above the 305.46 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 24, 2026.
Analysis
Neofect Co.Ltd (290660) currently trades at 1,771 KRW, while our model-based Fair Value estimate is 305.46 KRW, implying the stock looks roughly 479.7% overvalued today. The Quality Score stands at 15/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at 15.5B KRW. Revenue declined 16.0% year over year. It earns a return on equity of −31.9%. Net debt stands at 3.2B KRW. Fundamentals as of Aug 24, 2026
Our scenario range runs from 201.60 KRW (bear case) to 381.82 KRW (bull case); at 1,771 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 8% below its 52-week high and 177% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −83%, 290660 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when 290660 reaches fair value
Put 290660 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 21 · Market factors (momentum, volatility) 22
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Dynamic solution Co.,Ltd. researches, develops, manufactures, and sells rehabilitation medical devices and contents for stroke and spinal cord injuries.
Full company description
Dynamic solution Co.,Ltd. researches, develops, manufactures, and sells rehabilitation medical devices and contents for stroke and spinal cord injuries. The company offers Neofect Smart Glove, a high-tech rehab device that measures movements of the forearm, wrist, and digits with accelerometer and bending sensors; Neofect Smart Kids for hand rehabilitation in children; Neofect Smart Board, a high-tech medical device that develops users' shoulder and upper arm movements to promote improved functional reach and muscle control; Neofect Smart Balance to practice balance and posture during real-world training scenarios; and Neofect Smart Pegboard, a digital pegboard for functional and cognitive rehabilitation. It also provides Neofect Smart Table for dementia prevention and rehabilitation program; Neomano, a wearable robotic glove; Neofect Comcog, a cognitive rehabilitation program that helps patients with stroke, dementia, traumatic brain injury, brain tumor, and cerebral palsy; and Neofect TeleRehab, a teletherapy platform designed for remote rehabilitation, as well as a range of orthotic and assistive devices. The company was formerly known as Neofect Co., Ltd. and changed its name to Dynamic solution Co.,Ltd. in April 2026. The company was incorporated in 2010 and is headquartered in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Neofect Co.Ltd reported revenue of 16.1B KRW in FY2025 versus 23.2B KRW in FY2021, a compound −8.8%/yr. Reported net income was −12.3B KRW in FY2025.
290660 screens 480% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 364 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $90.78 | $41.02 | −55% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Neofect Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Neofect Co.Ltd (290660) overvalued or undervalued?
What is the fair value of 290660?
What is the quality score of 290660?
What is the revenue of Neofect Co.Ltd (290660)?
What is the net profit margin of 290660?
Watch Neofect Co.Ltd in the live analysis
One click puts Neofect Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.